Evidence quality
TB-500 and cardiac repair: the mice were positive and the human trial was not
Thymosin beta 4 prevented cardiac dysfunction and fibrosis in mice 28 days after ischaemia and reperfusion, and the effect vanished when the ErbB2 pathway was blocked. In a randomised, double-blind, placebo-controlled trial of 96 people with a heart attack, infarct size was significantly reduced in the subgroup dosed within 8 hours of angioplasty — and the difference across the whole trial was not significant.